Imaging-guided gene therapy of experimental gliomas

Cancer Research

Volumn 67, Issue 4, 2007, Pages 1706-1715

  Jacobs, Andreas H ^a   Rueger, Maria Adele ^a   Winkeler, Alexandra ^a   Li, Hongfeng ^a   Vollmar, Stefan ^a   Waerzeggers, Yannic ^a   Rueckriem, Benedikt ^a   Kummer, Christiane ^a   Dittmar, Claus ^a   Klein, Markus ^a   Heneka, Michael T ^a   Herrlinger, Ulrich ^a   Fraefel, Cornel ^a   Graf, Rudolf ^a   Wienhard, Klaus ^a   Heiss, Wolf Dieter ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUORODEOXYGLUCOSE F 18; GANCICLOVIR; GREEN FLUORESCENT PROTEIN; HERPESVIRUS VECTOR; METHIONINE C 11; THYMIDINE KINASE;

AMPLICON; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG POTENTIATION; GENE EXPRESSION; GLIOBLASTOMA; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMAGING SYSTEM; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL LINE, TUMOR; DIDEOXYNUCLEOSIDES; FLUORINE RADIOISOTOPES; GENE THERAPY; GLIOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, NUDE;

EID: 33847728953     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2418     Document Type: Article

References (64)

1. Kleihues P, Cavenee WK, editors. Pathology and genetics of tumours of the nervous system (WHO). Lyon: IARC Press; 2000.
2. Preston-Martin S. Epidemiology. In: Berger MS, Wilson CD, editors. The gliomas. Philadelphia (PA): Saunders; 1999. p. 2-11.
3. Tatter SB, Harsh GR. Current treatment modalities for brain tumor. In: Chiocca EA, Breakefield XO, editors. Gene therapy for neurological disorders and brain tumors. Totowa (NJ): Humana Press; 1998. p. 161-89.
4. Aboody-Guterman KS, Pechan PA, Rainov NG, et al. Green fluorescent protein as a reporter for retrovirus and helper virus-free HSV-1 amplicon vector-mediated gene transfer into neural cells in culture and in vivo. Neuroreport 1997;8:3801-8.
5. Fraefel C, Song S, Lim F, et al. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 1996;70:7190-7.
6. Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors. Part II. Vector systems and applications. Neoplasia 1999;1:402-16.
7. Jacobs A, Winkeler A, Hartung M, et al. Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes. Hum Gene Ther 2003;14:277-97.
8. Rueger MA, Winkeler A, Miletic H, et al. Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene Ther 2005;12:588-96.
9. Klatzmann D, Valery CA, Bensimon G, et al. A phase I/ II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 1998;9:2595-604.
10. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867-74.
11. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000;11:2389-401.
12. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997;3:1354-61.
13. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;7:859-66.
14. Shand N, Weber F, Mariani L, et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther 1999;10:2325-35.
15. Jacobs A, Voges J, Reszka R, et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 2001;358:727-9.
16. Tjuvajev JG, Stockhammer G, Desai R, et al. Imaging the expression of transfected genes in vivo. Cancer Res 1995;55:6126-32.
17. Tjuvajev JG, Joshi A, Callegari J, et al. A general approach to the non-invasive imaging of transgenes using cis-linked herpes simplex virus thymidine kinase. Neoplasia 1999;1:315-20.
18. Yu Y, Annala AJ, Barrio JR, et al. Quantification of target gene expression by imaging reporter gene expression in living animals. Nat Med 2000;6:933-7.
19. Jacobs A, Dubrovin M, Hewett J, et al. Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. Neoplasia 1999;1:154-61.
20. Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 1998;90:370-80.
21. 18F]FLT). J Radioanal Nucl Chem 2000;243:843-6.
22. 18F]fluoro-thymidine with 2,3-anhydro-5-O-(4,4-dimethoxytrityl)-thymidine. J Labelled Cpd Radiopharm 2000; 43:1211-8.
23. 18F]-2-fluoro-2-deoxy-D-glucose. J Cereb Blood Flow Metab 1984;4:212-23.
24. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50:1316-22.
25. Cizek J, Herholz K, Vollmar S, Schrader R, Klein J, Heiss WD. Fast and robust registration of PET and MR images of human brain. Neuroimage 2004;22:434-42.
26. 18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET. Nucl Med Biol 1998;25:175-80.
27. Yaghoubi S, Barrio JR, Dahlbom M, et al. Human pharmacokinetic and dosimetry studies of [(18)F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. J Nucl Med 2001;42:1225-34.
28. Jacobs A, Tjuvajev JG, Dubrovin M, et al. Positron-emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res 2001;61:2983-95.
29. Sandmair AM, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000;11:2197-205.
30. Trask TW, Trask RP, Aguilar-Cordova E, et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000;1:195-203.
31. Jacobs AH, Voges J, Kracht LW, et al. Imaging in gene therapy of patients with glioma. J Neurooncol 2003;65:291-305.
32. Harsh GR, Deisboeck TS, Louis DN, et al. Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J Neurosurg 2000;92:804-11.
33. Haberkorn U, Bellemann ME, Gerlach L, et al. Uncoupling of 2-fluoro-2-deoxyglucose transport and phosphorylation in rat hepatoma during gene therapy with HSV thymidine kinase. Gene Ther 1998;5:880-7.
34. Pantuck AJ, Berger F, Zisman A, et al. CL1-39: a noninvasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography. J Urol 2002;168:1193-8.
35. Soling A, Theiss C, Jungmichel S, Rainov NG. A dual function fusion protein of herpes simplex virus type 1 thymidine kinase and firefly luciferase for noninvasive in vivo imaging of gene therapy in malignant glioma. Genet Vaccines Ther 2004;2:7.
36. Yaghoubi SS, Barrio JR, Namavari M, et al. Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography. Cancer Gene Ther 2005;12:329-39.
37. Barton KN, Tyson D, Stricker H, et al. GENIS: gene expression of sodium iodide symporter for noninvasive imaging of gene therapy vectors and quantification of gene expression in vivo. Mol Ther 2003;8:508-18.
38. Qiao J, Doubrovin M, Sauter BV, et al. Tumor-specific transcriptional targeting of suicide gene therapy. Gene Ther 2002;9:168-75.
39. De A, Lewis XZ, Gambhir SS, Noninvasive imaging of lentiviral-mediated reporter gene expression in living mice. Mol Ther 2003;7:681-91.
40. Davidson BL, Breakefield XO. Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci 2003;4:353-64.
41. Cunningham C, Davison AJ. A cosmid-based system for constructing mutants of herpes simplex virus type 1. Virology 1993;197:116-24.
42. Saeki Y, Breakefield XO, Chiocca A. Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods Mol Med 2003;76:51-60.
43. Costantini LC, Fraefel C, Breakefield XO, Isacson O. Herpes simplex virus/adeno-associated virus hybrid vectors for gene transfer to neurons. Preparation and use. Methods Mol Med 2002;69:479.
44. Johnston KM, Jacoby DR, Pechan PA, et al. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum Gene Ther 1997;8:359-70.
45. 18F]Fluoro-3- hydroxymethylbutyl)guanine for in vivo measurement of suicide gene expression with PET. J Nucl Med 2001;42:1682-90.
46. Black ME, Newcomb TG, Wilson HM, Loeb LA. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci U S A 1996;93:3525-9.
47. Moolten FL, Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986;46:5276-81.
48. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274-83.
49. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A 1992;89:33-7.
50. Fischer U, Steffens S, Frank S, Rainov NG, Schulze-Osthoff K, Kramm CM. Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene 2005;24:1231-43.
51. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998;9:1323-33.
52. Rogulski KR, Kim JH, Kim SH, Freytag SO. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther 1997;8:73-85.
53. Moriuchi S, Wolfe D, Tamura M, et al. Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther 2002;9:584-91.
54. Grierson JR, Shields AF. Radiosynthesis of 3′-deoxy-3′-[(18) F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 2000;27: 143-56.
55. 18F]FLT; portrait of a proliferation marker. Eur J Nucl Med Mol Imaging 2002;29:165-9.
56. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-6.
57. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 2003;44:2027-32.
58. 18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. Cancer Res 2003;63:2681-7.
59. Choi SJ, Kim JS, Kim JH, et al. [([18])F]3′-deoxy-3′- fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 2005;32:653-9.
60. 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005;46:1948-58.
61. 18F-FDG. J Nucl Med 2005;46:945-52.
62. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002;29:1462-9.
63. Johnson M, Sato M, Burton J, Gambhir SS, Carey M, Wu L. Micro-PET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: the advantage of a cell-specific transcriptional targeting approach. Mol. Imaging 2005;4:463-72.
64. Hajitou A, Trepel M, Lilley CE, et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 2006;125:385-98.